Morphic Holding Inc (MORF)
NASDAQ (NMS) NASDAQ (NMS) Primary 
MORF STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.
MORF SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / July 28, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.
MORF INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Morphic Holding, Inc. and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / July 26, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. ("Morphic") (NASDAQ:MORF) and Eli Lilly and Company ("Eli Lilly") (NYSE: LLY). Investors who purchased Morphic and continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/MORF.
Why Is Morphic (MORF) Stock Up 75% Today?
Morphic (NASDAQ: MORF ) stock is rocketing higher on Monday after the company reached an acquisition agreement with Eli Lilly (NYSE: LLY ). With this agreement, Eli Lilly will acquire Morphic for $3.2 billion in cash.
Eli Lilly Buys Morphic for $3.2B
Eli Lilly (LLY) agreed to buy biopharmaceutical firm Morphic (MORF) at a significant premium, sending shares of Morphic skyrocketing Monday.
Eli Lilly Buys Bowel Disease Drug Developer Morphic In $3.2 Billion Deal
Eli Lilly will acquire biopharmaceutical firm Morphic Holding in a deal valued at $3.2 billion, both companies announced Monday, a transaction that includes an experimental medication for inflammatory bowel disease and treatments for other chronic diseases.
Eli Lilly's First Biotech Deal Of 2024, Buys Chronic Disease Player Morphic For $3.2B
Monday, Eli Lilly And Co LLY agreed to acquire Morphic Holding Inc MORF for $57 per share in cash, an aggregate of approximately $3.2 billion.
Eli Lilly to Buy Morphic for $3.2 Billion. Morphic Stock Surges 78%.
Eli Lilly agrees to pay $57 a share for Morphic, or a 79% premium to the stock's closing price of $31.84 on Friday.
Morphic's stock rockets after $3.2 billion buyout deal with Eli Lilly
Shares of Morphic Holding Inc. MORF, +0.03% rocketed 76% in premarket trading Monday, after the biopharmaceutical company announced an agreement to be acquired by Eli Lilly & Co. LLY, +1.83% in a cash deal valued at about $3.2 billion. Lilly's stock LLY, +1.83% tacked on 0.2% ahead of the open.
Eli Lilly to acquire Morphic Holding for $3.2 billion
Eli Lilly will acquire Morphic Holding for $3.2 billion, the companies said on Monday.
MORF NEWS: Johnson Fistel Continues Investigation on Behalf of Morphic Holding Shareholders
SAN DIEGO, CA / ACCESSWIRE / June 17, 2024 / Johnson Fistel, is investigating potential securities claims against Morphic Holding, Inc. (NASDAQ:MORF) on behalf of stockholders. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws.
